Media
-
Aug 24, 2020Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2...
-
Aug 18, 2020Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 study...
-
Aug 13, 2020WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the German Association of Statutory Sick Funds has agreed upon new pricing...
-
Aug 4, 2020Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare...
-
Jul 22, 2020TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband...
